

Neutrophil Gelatinase Associated Lipocalin as a predictor of acute kidney injury post coronary angiogram

Submission date 26/08/2011	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 13/03/2012	Overall study status Completed	☐ Protocol
Last Edited 18/01/2019	Condition category Urological and Genital Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Background and study aims

In Northern Ireland the rising number of patients with both chronic kidney disease (CKD) and heart disease is explained by many risk factors. These include age, high blood pressure, diabetes and obesity. Around 6000 coronary dye tests are performed each year in Northern Ireland. 20% of patients tested will have CKD and are at high risk of kidney damage due to the harmful dye used (contrast-induced nephropathy - CIN). Contrast dye is toxic to the kidney. Unfortunately there is no alternative to it and the number of patients who develop this complication is set to rise.

Acute kidney injury (AKI) is best avoided; once developed it dramatically increases risk of death, length of hospital stay and healthcare costs. Current tests fail to detect early AKI and there is a need for new markers of kidney damage. Neutrophil gelatinase associated lipocalin (NGAL) has the potential to detect AKI within a few hours of onset; we aim to study it in a high-risk CKD population.

This study aims to find out whether NGAL could be a useful marker of early CIN and see if it can predict severity of CIN, and to see if NGAL could be used to identify those at high risk of CIN.

Who can participate?

Patients at high risk of CIN will be identified prior to cardiac catheterisation at Craigavon Area Hospital between October 2011 and August 2013. All patients over the age of 18 with existing chronic renal failure, as shown by abnormal blood tests before the dye test, will be invited to take part. Men and women will both be invited.

What does the study involve?

A fluid drip will be given to help protect kidney function before the dye test. Blood samples will be collected directly before and after the dye test, and at 2, 4, 6, 24 and 48 hour time-points. Additional blood will be stored for possible future testing.

What are the possible benefits and risks of participating?

New markers to detect AKI early would help to treat patients who develop AKI sooner. If realised, this research has the potential to dramatically increase the safety of coronary dye testing and could greatly benefit patients both in Northern Ireland and further afield. The only risk to patients will be that of serial blood sampling, which may cause minor bleeding, pain or bruising. This will be reduced by using the smallest needle possible. All patients will have the same treatment.

Where is the study run from?

Craigavon Area Hospital (UK).

When is the study starting and how long is it expected to run for?

The study will run from October 2011 to August 2013.

Who is funding the study?

RANDOX laboratories.

Who is the main contact?

Dr Michael Connolly

Research Fellow

Cardiac Research

Craigavon Area Hospital

Contact information

Type(s)

Scientific

Contact name

Dr David Mc Eneaney

Contact details

Cardiology Unit

Craigavon Area Hospital

68 Lurgan Road

Portadown

United Kingdom

BT63 5QQ

+44 (0)2838 334 444

david.mceneaney@southerntrust.hscni.net

Additional identifiers

Protocol serial number

1.1 19/08/2011

Study information

Scientific Title

Neutrophil Gelatinase Associated Lipocalin (NGAL) as a predictor of acute kidney injury post coronary angiogram: a cohort observational study

Study objectives

Raised levels of NGAL at 4 hours post contrast angiogram will predict acute kidney injury, as evidenced by a rise in creatinine > 25% at 48 hours.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Observational

Study design

Cohort observational study

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Chronic Renal Disease

Interventions

Samples for serum and urine NGAL, serum cystatin C and serum creatinine will be collected directly pre- and post-contrast angiogram, and at 2, 4, 6, 24 and 48 hr time-points to allow time course analysis post catheterisation.

Patients will be followed up at 30 days and 1 year.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Post procedure biomarker elevation diagnostic for acute kidney injury

Key secondary outcome(s)

Major cardiac adverse events (MACE) at 30 days and one year:

1. Myocardial infarction
2. Stroke
3. Heart failure hospitalisation
4. Death

Completion date

03/08/2013

Eligibility

Key inclusion criteria

1. Age > 18 years
2. Presenting for angiogram with known chronic kidney disease (CKD) [glomerular filtration rate (GFR) < 60mls/min]

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Myocardial infarction (MI) or acute coronary syndrome within previous 6 weeks
2. Hospitalisation within previous 6 weeks
3. Decompensated heart failure
4. Inability to give informed consent

Date of first enrolment

15/10/2011

Date of final enrolment

03/08/2013

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

Cardiology Unit

Portadown

United Kingdom

BT63 5QQ

Sponsor information

Organisation

Randox Laboratories (UK)

ROR

<https://ror.org/04cte7x29>

Funder(s)

Funder type

Industry

Funder Name

Randox Laboratories (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2018	18/01/2019	Yes	No